Insufficient Analyzable Efficacy and Safety Datasets
Severity: criticalThe application does not provide analyzable efficacy and safety datasets which would allow for independent review by the FDA. The key supporting reference (NEOLEV2 publication) lacks sufficiently detailed presentation of efficacy and safety data for independent analysis, preventing conclusions on effectiveness and safety. Preliminary assessment of a later amendment also identified deficiencies.
Recommended response: Sponsor must provide complete, analyzable efficacy and safety datasets, including raw data and detailed methodology, to allow for independent FDA verification of results. Engage in pre-resubmission discussions with the agency regarding data content and format.
Inadequate Abuse Potential Assessment
Severity: majorThe abuse potential assessment needs to provide a detailed summary of phenobarbital's abuse potential and dependence liability, including all abuse-related data for phenobarbital and other barbiturates (e.g., epidemiological data). Cross-linkage to all other eCTD sections supporting conclusions is required. If relying on Sezaby, establish scientific appropriateness and provide patent certification/statement.
Recommended response: Revise the abuse potential assessment to include comprehensive data on phenobarbital and other barbiturates, ensuring proper cross-referencing within the eCTD. If relying on a listed drug, provide scientific justification and patent certification.
Unresolved Manufacturing Facility Inspection Observations
Severity: criticalFollowing pre-approval inspection of the manufacturing facility, FDA conveyed deficiencies. Satisfactory resolution of these observations is required before this NDA may be approved.
Recommended response: Address all deficiencies identified during the pre-approval inspection of the manufacturing facility and provide documentation of satisfactory resolution to the agency.
Required Safety Update for Resubmission
Severity: majorWhen responding to deficiencies, include a safety update as described at 21 CFR 314.50(d)(5)(vi)(b). This includes describing significant changes, presenting new safety data, combining with original data, comparing frequencies, providing separate tables for other indications, retabulating premature discontinuations, providing case report forms/narratives for deaths/serious AEs, describing changes in common AEs, updating exposure information, summarizing worldwide experience, and providing English translations of foreign labeling.
Recommended response: Prepare a comprehensive safety update in accordance with 21 CFR 314.50(d)(5)(vi)(b), incorporating all new safety data, updated analyses, and required documentation for all clinical studies.
Cited: 21 CFR 314.50(d)(5)(vi)(b)
Biowaiver Request Contingent on Efficacy/Safety
Severity: infoThe FDA’s recommendation on the approvability of your biowaiver request for the proposed Phenobarbital Sodium Injection 90 mg/mL is contingent on the submission of adequate and acceptable information/data showing evidence of acceptable safety and efficacy findings in the target patient population for the proposed indication. This is an additional comment and not an approvability issue.
Recommended response: Note that the biowaiver approval is dependent on resolving the primary clinical efficacy and safety deficiencies. No immediate action on the biowaiver itself is required until clinical data is sufficient.
Labeling Comments Reserved
Severity: infoFDA reserves comment on the proposed labeling until the application is otherwise adequate. The agency encourages review of labeling review resources and use of the Selected Requirements for Prescribing Information (SRPI) checklist.
Recommended response: Review FDA labeling resources and the SRPI checklist in preparation for future labeling revisions once clinical and manufacturing deficiencies are resolved.
